Venmax Drugs & Pharmaceuticals Inc
Fundamental Score
Venmax Drugs & Pharmaceuticals Inc Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of VENMAX across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (106.67%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (676.47%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Excellent EPS Growth (19.57% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (19.57% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Below-Average Return on Equity (6.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.29%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 45.94x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Negative Free Cash Flow (₹-0.12 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Low Promoter Commitment (23.13%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Venmax Drugs & Pharmaceuticals Inc
About VENMAX
Business Overview
Venmax Drugs and Pharmaceuticals Limited engages in the business of pharmaceutical products, drug intermediaries, and API's. The company was formerly known as Yenkey Drugs & Pharmaceuticals Ltd and changed its name to Venmax Drugs and Pharmaceuticals Limited in April 2009. Venmax Drugs and Pharmaceuticals Limited was incorporated in 1988 and is based in Hyderabad, India.
Company Details
Key Leadership
Latest News
VENMAX Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Venmax Drugs & Pharmaceuticals Inc (VENMAX)?
As of 29 Jan 2026, 10:34 am IST, Venmax Drugs & Pharmaceuticals Inc (VENMAX) is currently trading at ₹24.56. The stock has a market capitalization of ₹15.62 (Cr).
Is VENMAX share price Overvalued or Undervalued?
VENMAX is currently trading at a P/E ratio of 45.94x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Venmax Drugs & Pharmaceuticals Inc share price?
Key factors influencing VENMAX's price include its quarterly earnings growth (Sales Growth: 676.47%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Venmax Drugs & Pharmaceuticals Inc a good stock for long-term investment?
Venmax Drugs & Pharmaceuticals Inc shows a 5-year Profit Growth of 19.57% and an ROE of 6.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.36 before investing.
How does Venmax Drugs & Pharmaceuticals Inc compare with its industry peers?
Venmax Drugs & Pharmaceuticals Inc competes with major peers in the Pharmaceuticals. Investors should compare VENMAX's P/E of 45.94x and ROE of 6.38% against the industry averages to determine its competitive standing.
What is the P/E ratio of VENMAX and what does it mean?
VENMAX has a P/E ratio of 45.94x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹46 for every ₹1 of annual earnings.
How is VENMAX performing according to Bull Run's analysis?
VENMAX has a Bull Run fundamental score of 41.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does VENMAX belong to?
VENMAX operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Venmax Drugs & Pharmaceuticals Inc.
What is Return on Equity (ROE) and why is it important for VENMAX?
VENMAX has an ROE of 6.38%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Venmax Drugs & Pharmaceuticals Inc generates profits from shareholders' equity.
How is VENMAX's debt-to-equity ratio and what does it indicate?
VENMAX has a debt-to-equity ratio of 0.36, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is VENMAX's dividend yield and is it a good dividend stock?
VENMAX offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has VENMAX grown over the past 5 years?
VENMAX has achieved 5-year growth rates of: Sales Growth 11.50%, Profit Growth 19.57%, and EPS Growth 19.57%.
What is the promoter holding in VENMAX and why does it matter?
Promoters hold 23.13% of VENMAX shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is VENMAX's market capitalization category?
VENMAX has a market capitalization of ₹16 crores, placing it in the Small-cap category.
How volatile is VENMAX stock?
VENMAX has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for VENMAX?
VENMAX has a 52-week high of ₹N/A and low of ₹N/A.
What is VENMAX's operating profit margin trend?
VENMAX has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is VENMAX's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 676.47% and YoY Profit Growth of 106.67%.
What is the institutional holding pattern in VENMAX?
VENMAX has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.